Skip to main content
. 2023 Jan 24;14(3):364–375. doi: 10.1111/jdi.13938

Figure 2.

Figure 2

A total of 14 differential genes that Sinomenium acutum might act on to treat diabetic peripheral neuropathy (DPN) are screened. (a) Heat map of the differential genes in the GSE95849 microarray (C represents control group [n = 6], and T represents diabetic peripheral neuropathic pain [DPNP] group [n = 6]. Blue indicates down‐regulation and yellow indicates upregulation). (b) Volcanic map of the differential genes in the GSE95849 microarray (n = 6 for the control and DPNP groups, respectively. Black dots represent genes that are not differentially expressed, red dots represent the upregulated genes and green dots represent downregulated genes). (c) Venn diagram for the intersection of differential genes in GSE95849 microarray and effective target genes obtained from network pharmacological analysis (the bar chart below shows the number of differential genes in DPNP and S. acutum). (d) Network diagram of “Sinomenium acutum‐ingredients‐target” (green circles represent the active ingredients of S. acutum and red diamonds represent the target genes which the active ingredients act on). (e) Bar chart of gene ontology function analysis of the 14 candidate genes at the biological process (BP), cellular component (CC) and molecular function (MF) levels. (f) Bar chart of the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the 14 candidate genes.